Oyster Point Pharma, Inc. (OYST)

NASDAQ: OYST · IEX Real-Time Price · USD
6.13
-0.36 (-5.55%)
Sep 27, 2022 4:00 PM EDT - Market closed
-5.55%
Market Cap 164.48M
Revenue (ttm) 31.94M
Net Income (ttm) -157.57M
Shares Out 26.83M
EPS (ttm) -4.95
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 42,972
Open 7.18
Previous Close 6.49
Day's Range 5.94 - 7.22
52-Week Range 3.46 - 19.98
Beta 1.01
Analysts Buy
Price Target 29.17 (+375.9%)
Earnings Date Nov 2, 2022

About OYST

Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, Ne... [Read more...]

Industry Biotechnology
IPO Date Oct 31, 2019
Employees 303
Stock Exchange NASDAQ
Ticker Symbol OYST
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for OYST stock is "Buy." The 12-month stock price forecast is 29.17, which is an increase of 375.86% from the latest price.

Price Target
$29.17
(375.86% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Oyster Point Pharma to Present New Scientific Analyses at World Cornea Congress VIII

Two Featured Presentations will Include a Post-Hoc Analysis of TYRVAYA® (varenicline solution) Nasal Spray and Tear Film Cytokine Research Two Featured Presentations will Include a Post-Hoc Analysis of ...

9 hours ago - GlobeNewsWire

Oyster Point Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the disc...

2 weeks ago - GlobeNewsWire

Oyster Point Pharma to Present Analyses at the Women in Ophthalmology Summer Symposium

PRINCETON, N.J., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of ...

1 month ago - GlobeNewsWire

Oyster Point Pharma Announces TYRVAYA® To Be Covered By the Largest Medicare Pharmacy Benefit Manager

PRINCETON, N.J., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discov...

1 month ago - GlobeNewsWire

OYSTER PT PHARM (OYST) Reports Q2 Loss, Lags Revenue Estimates

OYSTER PT PHARM (OYST) delivered earnings and revenue surprises of -14.02% and 2.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Oyster Point Pharma Reports Second Quarter 2022 Financial Results and Recent Business Highlights

PRINCETON, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discov...

1 month ago - GlobeNewsWire

Oyster Point Pharma To Report Second Quarter 2022 Financial Results On August 11, 2022

Conference Call and Webcast Scheduled for August 11, 2022, 4:30 p.m. ET

1 month ago - GlobeNewsWire

Oyster Point Pharma Announces Expanded Patient Access to TYRVAYA®

PRINCETON, N.J., July 27, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discov...

2 months ago - GlobeNewsWire

Wall Street Analysts Think OYSTER PT PHARM (OYST) Could Surge 423%: Read This Before Placing a Bet

The consensus price target hints at a 423.5% upside potential for OYSTER PT PHARM (OYST). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings es...

2 months ago - Zacks Investment Research

Oyster Point Pharma Announces Operating Expense Streamlining Plan

Plan to Continue to Drive TYRVAYA ® Launch with Approximately 150-200 Field-Based Sales Resources

2 months ago - GlobeNewsWire

Oyster Point Pharma Research Selected for Top 5 Poster Session at American Optometric Association's Optometry's Meeting®

Scientific Poster Examines Effects of Treatment in Broad Spectrum of Dry Eye Disease Patients Scientific Poster Examines Effects of Treatment in Broad Spectrum of Dry Eye Disease Patients

3 months ago - GlobeNewsWire

OYSTER PT PHARM (OYST) Reports Q1 Loss, Tops Revenue Estimates

OYSTER PT PHARM (OYST) delivered earnings and revenue surprises of -2.86% and 31.58%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Oyster Point Pharma Reports First Quarter 2022 Financial Results and Recent Business Highlights

PRINCETON, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discove...

4 months ago - GlobeNewsWire

Oyster Point Pharma To Report First Quarter 2022 Financial Results On May 5, 2022

Conference Call and Webcast Scheduled for May 5, 2022, 4:30 p.m. ET Conference Call and Webcast Scheduled for May 5, 2022, 4:30 p.m. ET

4 months ago - GlobeNewsWire

Oyster Point Pharma to Participate in the Cowen 42nd Annual Health Care Conference

Conference Call and Webcast Scheduled for March 7, 2022, 10:30 A.M. ET Conference Call and Webcast Scheduled for March 7, 2022, 10:30 A.M. ET

6 months ago - GlobeNewsWire

OYSTER PT PHARM (OYST) Reports Q4 Loss, Tops Revenue Estimates

OYSTER PT PHARM (OYST) delivered earnings and revenue surprises of -15.83% and 1,206.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Oyster Point Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights

PRINCETON, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discov...

7 months ago - GlobeNewsWire

Oyster Point Pharma To Report Fourth Quarter And Full Year 2021 Financial Results On February 24, 2022

Conference Call and Webcast Scheduled for February 24, 2022, 4:30 p.m. ET Conference Call and Webcast Scheduled for February 24, 2022, 4:30 p.m. ET

7 months ago - GlobeNewsWire

Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of ...

8 months ago - GlobeNewsWire

Oyster Point Pharma to Present at Upcoming Investor Conferences in January 2022

PRINCETON, N.J., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of f...

9 months ago - GlobeNewsWire

Oyster Point Pharma Announces Addition To Nasdaq Biotechnology Index

PRINCETON, N.J., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of f...

9 months ago - GlobeNewsWire

Oyster Point Pharma to Participate in the Piper Sandler 33rd Annual Healthcare Conference

PRINCETON, N.J., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of f...

9 months ago - GlobeNewsWire

Oyster Point Pharma Announces Expansion of Executive Leadership Team to Support Commercialization of Tyrvaya™ (vareni...

PRINCETON, N.J., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of f...

10 months ago - GlobeNewsWire

Oyster Point Pharma to Present Data at the American Academy of Ophthalmology Annual Meeting 2021

PRINCETON, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of f...

10 months ago - GlobeNewsWire

Oyster Point Pharma's TYRVAYA™ (varenicline solution) Nasal Spray is Now Available at U.S. Regional Wholesalers for D...

PRINCETON, N.J., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), today announced that TYRVAYA™ (varenicline solution) Nasal Spray 0.03 mg is now available at U.S. regional wh...

10 months ago - GlobeNewsWire